Media

Orthocell shares spike 350% following interim results of Celgro nerve regeneration study

by scott forrest

May 14, 2019

Orthocell CEO Paul Anderson spoke to BioWorld Asia about the interim results of our nerve regeneration trial, that saw patients regain sensation and muscle function following Celgro™ nerve regeneration treatment. Read the article HERE.

We detected you're visiting from Australia. Would you like to switch to the AU version of this site?